Tag: life sciences
-
Univ. Engineers Convert CPAP into Ventilator
An engineering group found a way to adapt a CPAP machine into a mechanical ventilator, a device for people needing breathing help from Covid-19 infections.
-
Covid-19 Vaccine in Development, Trial Planned
A biotechnology company specializing in infectious diseases is developing a vaccine to protect against Covid-19 infections, with a clinical trial to start next month.
-
Trial to Test Convalescent Antibodies for Covid-19
A group of Canadian academic labs and hospitals will begin a clinical trial testing antibodies from recovered Covid-19 patients as a treatment for the disease.
-
Trial to Test Electronic-Aided Covid-19 Vaccine
A company developing cancer immunotherapies is adapting its electronic-assisted process to create a vaccine protecting against Covid-19 infections.
-
Employers, Patients See Discounts from Biosimilars
An analysis of health care spending by large employers shows both companies and their employees are saving money from using non-branded biologic therapies.
-
Life Science Venture Funds Raise $2.56B for Start-Ups
Two investment companies specializing in health care and life sciences revealed new venture funds to finance young enterprises with innovative technologies.
-
Trial to Test Malaria Drug to Stop Covid-19
A registry and clinical trial of health care workers aims to document effects of hydroxychloroquine, a widely available malaria drug, to prevent Covid-19 infections.
-
Trial Shows Rare Disease Drug Treats Covid-19 Patients
Results from a clinical trial show a drug approved for a rare lymph node disease can stabilize or improve the condition of many people with severe Covid-19 complications.
-
Phone App Tracking Covid-19 Symptom Reports
A smartphone app is collecting individual reports about Covid-19 symptoms and other health conditions to provide earlier warnings of outbreaks to health authorities.
-
Start-Up Licenses Immunotherapies in $880M Deal
A new biotechnology enterprise creating treatments that alter chemical functions in immune cells agreed to license its technology to a pharmaceutical company.